Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Whole body MRI is effective for identifying metastatic disease in colorectalcancer patients. The studyTaylor S, Mallett S, Beare S et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectalcancer: the prospective Streamline C trial. Lancet Gastroenterol Hepatol 2019;4:529-37.This project was funded by the NIHR Health Technology Assessment Programme (project number 10/68/01).To read the full NIHR Signal, go to https (...) ://discover.dc.nihr.ac.uk/content/signal-000797/identifying-metastatic-disease-in-colorectal-cancer-with-whole-body-mri.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Follow-up strategies for patients treated for non-metastatic colorectalcancer. This is the fourth update of a Cochrane Review first published in 2002 and last updated in 2016.It is common clinical practice to follow patients with colorectalcancer for several years following their curative surgery or adjuvant therapy, or both. Despite this widespread practice, there is considerable controversy about how often patients should be seen, what tests should be performed, and whether these varying (...) strategies have any significant impact on patient outcomes.To assess the effect of follow-up programmes (follow-up versus no follow-up, follow-up strategies of varying intensity, and follow-up in different healthcare settings) on overall survival for patients with colorectalcancer treated with curative intent. Secondary objectives are to assess relapse-free survival, salvage surgery, interval recurrences, quality of life, and the harms and costs of surveillance and investigations.For this update, on 5
Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancer Colonic J pouch reconstruction has been found to be associated with a lower incidence of anastomotic leakage than straight anastomosis. However, studies on this topic are underpowered and retrospective. This randomized trial evaluated whether the incidence of anastomotic leakage was reduced after colonic J pouch reconstruction compared (...) with straight colorectal anastomosis following anterior resection for rectal cancer.This multicentre RCT included patients with rectal carcinoma who underwent low anterior resection followed by colorectal anastomosis. Patients were assigned randomly to receive a colonic J pouch or straight colorectal anastomosis. The main outcome measure was the occurrence of major anastomotic leakage. The incidence of global (major plus minor) anastomotic leakage and general complications were secondary outcomes. Risk
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectalcancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial Microsatellite-stable metastatic colorectalcancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus cobimetinib in metastatic colorectalcancer. Here, we report the comparison of atezolizumab plus cobimetinib or atezolizumab monotherapy versus (...) regorafenib in the third-line setting.IMblaze 370 is a multicentre, open-label, phase 3, randomised, controlled trial, done at 73 academic medical centres and community oncology practices in 11 countries. Patients aged at least 18 years with unresectable locally advanced or metastatic colorectalcancer, baseline Eastern Cooperative Oncology Group performance status of 0-1, and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled. We used permuted
Towards risk-stratified colorectalcancer screening. Adding risk factors to the fecal immunochemical test: Evidence, evolution and expectations With increasing incidence and mortality, colorectalcancer (CRC) is a growing health problem worldwide. An effective way to address CRC is by screening for fecal (occult) blood by the fecal immunochemical test (FIT). However, there is room for improvement since precursor lesions and CRC bleed intermittent and can therefore be missed by the FIT (false
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic ColorectalCancer: The SUNSHINE Randomized Clinical Trial In observational studies, higher plasma 25-hydroxyvitamin D (25[OH]D) levels have been associated with improved survival in metastatic colorectalcancer (CRC).To determine if high-dose vitamin D3 added to standard chemotherapy improves outcomes in patients with metastatic CRC.Double-blind phase 2 (...) randomized clinical trial of 139 patients with advanced or metastatic CRC conducted at 11 US academic and community cancer centers from March 2012 through November 2016 (database lock: September 2018).mFOLFOX6 plus bevacizumab chemotherapy every 2 weeks and either high-dose vitamin D3 (n = 69) or standard-dose vitamin D3 (n = 70) daily until disease progression, intolerable toxicity, or withdrawal of consent.The primary end point was progression-free survival (PFS) assessed by the log-rank test
Primary Tumor Resection in Patients with Incurable Localized or Metastatic ColorectalCancer: A Systematic Review and Meta-analysis To assess the impact of primary tumor resection (PTR) on survival and morbidity in incurable colorectal cancer.Systematic literature review and meta-analysis to compare PTR versus primary tumor intact (PTI).Seventy-seven studies were included, reporting on 159,991 participants (94,745 PTR; 65,246 PTI). PTR improved overall survival (hazard ratio [HR] 0.59, P (...) % morbidity (obstruction 14.4%, anemia 11.0%, hemorrhage 1.5%, perforation 0.6%, adverse events requiring surgery 15.8%). NRS resulted in 10.6% perioperative mortality and 21.7% morbidity (major 7.9%, minor 21.7%, reoperation 0.1%).PTR in patients with incurable colorectalcancer results in a limited improvement of survival without a significant increase in morbidity. PTR should be considered by the multidisciplinary team on an individual patient basis.
Clinical practice guidelines for the prevention, early detection and management of colorectalcancer Clinical practice guidelines for the prevention, early detection and management of colorectalcancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer (...) , and developed for health professionals practising in an Australian health care setting. This publication reflects the views of the authors and not necessarily the views of the Australian Government. Cite this guideline Cancer Council Australia Colorectal Referring to the large bowel, comprising the colon and rectum. Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectalcancer. Sydney: Cancer Council Australia. [Version URL: , cited
Participation and Ease of Use in ColorectalCancer Screening: A Comparison of 2 Fecal Immunochemical Tests The impact of fecal immunochemical test (FIT)-based colorectalcancer (CRC) screening on disease incidence and mortality is affected by participation, which might be influenced by ease of use of the FIT. We compared the participation rates and ease of use of 2 different FITs in a CRC screening program.There were two study designs within the Dutch CRC screening program. In a paired cohort
Treatment of Patients with Early-Stage ColorectalCancer Resource-Stratified Guideline Treatment of Patients With Early-Stage ColorectalCancer: ASCO Resource-Stratified Guideline | Journal of Global Oncology Search in: Menu Article Tools SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JGO.18.00214 Journal of Global Oncology - published online before print February 25, 2019 PMID: Treatment of Patients With Early-Stage (...) ColorectalCancer: ASCO Resource-Stratified Guideline , MD, MPH 1 x Ainhoa Costas-Chavarri ; , MD 2 3 x Govind Nandakumar ; , MSPH 4 x Sarah Temin ; , MD, MBA 5 x Gilberto Lopes ; , MD, PhD 6 x Andres Cervantes ; , MD, PhD 7 8 x Marcia Cruz Correa ; , MD 9 x Rena Engineer ; , MD, PhD 10 x Chisato Hamashima ; , MD 11 x Gwo Fuang Ho ; , MD 12 x Fidel David Huitzil ; , MD 13 x Mona Malekzadeh Moghani ; , MD 14 x Ala I. Sharara ; , PhD 15 x Mariana C. Stern ; , MD 16 x Catherine Teh ; , MD 12 x Sara E
Early Detection for ColorectalCancer Resource-Stratified Guideline Early Detection for ColorectalCancer: ASCO Resource-Stratified Guideline | Journal of Global Oncology Search in: Menu Article Tools SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JGO.18.00213 Journal of Global Oncology - published online before print February 25, 2019 PMID: Early Detection for ColorectalCancer: ASCO Resource-Stratified Guideline , MD, MBA 1 (...) Yantiss ; and , MD, PhD 16 x Marcia Cruz Correa 1 University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL 2 Keck School of Medicine of University of Southern California, Los Angeles, CA 3 American Society of Clinical Oncology, Alexandria, VA 4 American University of Beirut, Beirut, Lebanon 5 Hospital Clinico Universitario, Valencia, Spain 6 Rwanda Military Hospital, Kigali, Rwanda 7 Tata Memorial Centre, Mumbai, India 8 National Cancer Center, Tokyo, Japan 9 University of Malaya, Kuala
Randomized clinical trial of selective decontamination of the digestive tract in elective colorectalcancer surgery (SELECT trial) Infectious complications and anastomotic leakage affect approximately 30 per cent of patients after colorectalcancer surgery. The aim of this multicentre randomized trial was to investigate whether selective decontamination of the digestive tract (SDD) reduces these complications of elective colorectalcancer surgery.The effectiveness of SDD was evaluated (...) in a multicentre, open-label RCT in six centres in the Netherlands. Patients with colorectalcancer scheduled for elective curative surgery with a primary anastomosis were eligible. Oral colistin, tobramycin and amphotericin B were administered to patients in the SDD group to decontaminate the digestive tract. Both treatment and control group received intravenous cefazolin and metronidazole for perioperative prophylaxis. Mechanical bowel preparation was given for left-sided colectomies, sigmoid and anterior
Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in ColorectalCancer MINI: In the present study, we systemically and comprehensively evaluated the prognostic significance of a combination of inflammatory factors using preoperative blood examination, and focused on the potential feasibility of our newly developed lymphocyte-CRP ratio (LCR) as a prognostic biomarker in CRC patients. We have firstly identified that a combination (...) of inflammatory factors using preoperative blood, and to assess the clinical significance of our newly developed inflammatory score in colorectalcancer (CRC) patients.In total 477 CRC patients from the discovery and validation cohorts were enrolled in this study. We assessed the predictive impact for recurrence using a combination of nine inflammatory markers in the discovery set, and focused on lymphocyte-C-reactive protein ratio (LCR) to elucidate its prognostic and predictive value for peri-operative risk
Aspirin Use to Prevent Cardiovascular Disease and ColorectalCancer 1 Aspirin Use to Prevent Cardiovascular Disease and ColorectalCancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including
Familial colorectalcancer risk in half siblings and siblings: nationwide cohort study. To explore the risk of colorectalcancer in family members of patients with colorectalcancer, with an emphasis on subtypes of second degree relatives, especially half siblings, which were lacking in the literature.Ambidirectional cohort study.Nationwide Swedish Family Cancer Data (record linkage).All people residing in Sweden and born after 1931, with their biological parents, totalling >16 million (...) individuals (follow-up: 1958-2015); of those with clear genealogy, 173 796 developed colorectal cancer.Lifetime (0-79 years) cumulative risk and standardised incidence ratio of colorectalcancer among first degree relatives and second degree relatives.The overall lifetime cumulative risk of colorectalcancer in siblings of patients was 7%, which represents a 1.7-fold (95% confidence interval 1.6 to 1.7; n=2089) increase over the risk in those without any family history of colorectalcancer. A similarly
Robotic Versus Conventional Laparoscopic Surgery for ColorectalCancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis Minimally invasive surgery has been considered as an alternative to open surgery by surgeons for colorectalcancer. However, the efficacy and safety profiles of robotic and conventional laparoscopic surgery for colorectalcancer remain unclear in the literature. The primary aim of this review was to determine whether robotic-assisted laparoscopic surgery (...) (RAS) has better clinical outcomes for colorectalcancer patients than conventional laparoscopic surgery (CLS).All randomized clinical trials (RCTs) and observational studies were systematically searched in the databases of CENTRAL, EMBASE and PubMed from their inception until January 2018. Case reports, case series and non-systematic reviews were excluded.Seventy-three studies (6 RCTs and 67 observational studies) were eligible (n = 169,236) for inclusion in the data synthesis. In comparison
Screening for colorectalcancer-where does the fit-DNA test fit? Screening for Colorectalcancer-Where does the FIT-DNA test fit? – Clinical Correlations Search Screening for Colorectalcancer-Where does the FIT-DNA test fit? February 21, 2019 6 min read . Almost all CRC develops from precancerous polyps, and with appropriate colonoscopy screening most polyps can be detected and removed before they transform into cancer. Simply put, CRC screening saves lives. ; however, over 40% of . Perhaps (...) compared to FIT alone. Based on the data currently available, one can expect 23.6% of patients with a positive FIT-DNA to have an advanced precancerous lesion or colorectalcancer on colonoscopy compared to 32.8% of patients following a positive FIT. 5 Over 50% of patients with positive results using either test will have a polyp. Modeling has estimated minimal difference, but FIT-DNA may lead to slightly more complications following screening (vs FIT) due to the increased colonoscopy usage (12 versus
Clinical Utility Card - Heritable mutations which increase risk in colorectal and endometrial cancer 1 Public Summary Document Application No. 1504 - Heritable mutations which increase risk in colorectal and endometrial cancer Applicant: The Royal College of Pathologists of Australasia (RCPA) Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application (...) An application requesting Medicare Benefits Schedule (MBS) listing for genetic testing to identify inheritable mutations predisposing to colorectal and endometrial cancer, specifically the identification of heritable mutations associated with the clinical presentations of Lynch Syndrome (LS), Familial Adenomatous Polyposis (FAP), MUTYH-Associated Polyposis (MAP), Juvenile Polyposis Syndrome (JPS), Peutz-Jeghers Syndrome (PJS), and Hereditary Mixed Polyposis Syndrome (HMPS), was received from the RCPA
Performance Characteristics of Fecal Immunochemical Tests for ColorectalCancer and Advanced Adenomatous Polyps: A Systematic Review and Meta-analysis. Studies report inconsistent performance of fecal immunochemical tests (FITs) for colorectalcancer (CRC) and advanced adenomas.To summarize performance characteristics of FITs for CRC and advanced adenomas in average-risk persons undergoing screening colonoscopy (reference standard) and to identify factors affecting these characteristics.Ovid